Arrowhead presents preclinical results on ARO-ALK7
ALK7, the company’s investigational RNA interference therapeutic targeting Activin receptor-like kinase 7 being developed as a potential treatment for obesity. The results were presented in a poster ...
Arrowhead Pharmaceuticals Presents Preclinical Data on ARO-ALK7 for Treatment of Obesity
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced preclinical results on ARO-ALK7, the company’s investigational RNA interference (RNAi) therapeutic targeting Activin receptor-like kinase ...
State of New Jersey Common Pension Fund D Increases Stock Position in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR)
State of New Jersey Common Pension Fund D raised its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR – ...
Arrowhead Pharmaceuticals (ARWR): Among the Most Oversold Healthcare Stocks to Buy Now
We recently published a list of the 12 Most Oversold Healthcare Stocks to Buy Now. In this article, we are going to take a ...
Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions
Arrowhead Pharmaceuticals stock could remain under pressure in the near-term, but improved financial outlook and pipeline ...
Fat, not muscle: drugmakers in race for next weight-loss breakthrough
European Union trade chief Maros Sefcovic said on Thursday that his top priority in trade talks with President Donald Trump's ...
20 stocks of companies expected to put up numbers to back investors' new 'growth mindset'
For small-cap stocks, a commonly cited benchmark is the Russell 2000 RUT. It is made up of the 2,000 companies in the full Russell 3000 Index RUA, which itself is designed to capture 98% of the market ...
FY2025 Earnings Estimate for ARWR Issued By B. Riley
Stock analysts at B. Riley raised their FY2025 earnings per share estimates for Arrowhead Pharmaceuticals in a report issued ...